Business Description
Maze Therapeutics is a clinical-stage company based in South San Francisco that develops oral medicines targeting the underlying genetic causes of kidney and metabolic diseases. Its most advanced programs are focused on APOL1-related kidney disease and phenylketonuria, both of which have candidates currently in or near Phase II clinical trials. The company also has a program in development for Pompe disease and maintains partnerships with Shionogi, Neurocrine Biosciences, and Trace Neuroscience to advance additional research efforts. Founded in 2017, Maze operates under its current name after rebranding from Modulus Therapeutics in 2018.
